Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Common Equity: 2013-2017

Historic Common Equity for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $99.1 million.

  • Tvardi Therapeutics' Common Equity rose 37.98% to $99.1 million in Q3 2017 from the same period last year, while for Sep 2017 it was $99.1 million, marking a year-over-year increase of 37.98%. This contributed to the annual value of $50.7 million for FY2016, which is 51.71% down from last year.
  • As of Q3 2017, Tvardi Therapeutics' Common Equity stood at $99.1 million, which was down 9.29% from $109.2 million recorded in Q2 2017.
  • Tvardi Therapeutics' 5-year Common Equity high stood at $113.9 million for Q3 2015, and its period low was -$55.3 million during Q1 2013.
  • For the 3-year period, Tvardi Therapeutics' Common Equity averaged around $76.9 million, with its median value being $82.6 million (2016).
  • In the last 5 years, Tvardi Therapeutics' Common Equity surged by 227.13% in 2014 and then tumbled by 69.17% in 2017.
  • Over the past 5 years, Tvardi Therapeutics' Common Equity (Quarterly) stood at -$54.1 million in 2013, then soared by 195.54% to $51.7 million in 2014, then skyrocketed by 103.33% to $105.0 million in 2015, then tumbled by 51.71% to $50.7 million in 2016, then soared by 37.98% to $99.1 million in 2017.
  • Its Common Equity stands at $99.1 million for Q3 2017, versus $109.2 million for Q2 2017 and $29.3 million for Q1 2017.